Table 5.
CGM Studies in the Non-ICU in Adult Populations.
| Patient population | CGM type | CGM manufacturer | Performance measurement | Comparator | |
|---|---|---|---|---|---|
| Dungan et al97 | T1DM and T2DM (n: 58), on intravenous or subcutaneous insulin | iPro system | Medtronic MiniMed | Accuracy | Capillary by POC |
| Burt et al98 | T1DM and T2DM, on basal bolus insulin (n: 26) | System Gold | Medtronic MiniMed | Accuracy and glycemic control | Capillary by POC |
| Schaupp et al99 | T2DM, on basal bolus insulin (n: 84) | iPro2 system | Medtronic MiniMed | Accuracy | Capillary by POC |
| Gómez et al93 | T2DM, on basal bolus insulin (n: 38) | iPro2 system | Medtronic MiniMed | Glycemic control and hypoglycemia detection | Capillary by POC |
| Spanakis et al100 | T2DM, on insulin therapy (n: 5) | Dexcom G4 CGM with Share2 application | Dexcom | Glucose telemetry system feasibility | None |
| Singh et al101 | T2DM, on basal-bolus insulin (n: 13) | Dexcom G4 Platinum CGM | Dexcom | Feasibility and prevention of hypoglycemia | Blinded CGM |
| Nair et al102 | Surgical ward (n: 10) | Dexcom G6 Blinded | Dexcom | Accuracy | Capillary by POC |
| Shehav-Zaltman et al40 | T1DM on CSII (n: 1) and T2DM on basal bolus (n: 3), COVID-19 wards (n: 5) | Guardian | Medtronic MiniMed | Feasibility | None |
| Galindo et al96 | T2DM, on basal-bolus insulin (n: 97) | FreeStyle Libre Pro CGM | Abbott Diabetes Care | Accuracy and hypoglycemia detection | Capillary by POC |
| Singh et al43 | T2DM, on basal-bolus insulin (n: 72) | Dexcom G6 | Dexcom | Prevention of hypoglycemia | Blinded CGM |
| Ushigome et al103 | Diabetes (unknown type) with COVID-19 (n: 1) | Dexcom G4 Platinum | Dexcom | Safety and effectiveness | Lab |
CSII, continuous subcutaneous insulin infusion; POC, point of care; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.